1,969 Astera Labs, Inc. $ALAB Shares Sold by Fairvoy Private Wealth LLC

Posted by Stanley Muller on Oct 19th, 2026

Fairvoy Private Wealth LLC lessened its stake in shares of Astera Labs, Inc. (NASDAQ:ALAB – Free Report) by 54.8% during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 1,623 shares of the company’s stock after selling 1,969 shares during the period. Fairvoy Private Wealth LLC’s holdings in Astera Labs were worth $578,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. BlackRock Inc. bought a new stake in Astera Labs in the second quarter worth $6,609,581,000. Atreides Management LP increased its position in Astera Labs by 108.9% during the first quarter. Atreides Management LP now owns 3,365,787 shares of the company’s stock valued at $368,890,000 after acquiring an additional 1,754,593 shares during the last quarter. Van ECK Associates Corp increased its position in Astera Labs by 20.0% during the second quarter. Van ECK Associates Corp now owns 2,237,961 shares of the company’s stock valued at $1,080,980,000 after acquiring an additional 373,545 shares during the last quarter. Bank of America Corp DE purchased a new stake in shares of Astera Labs in the second quarter valued at $1,061,791,000. Finally, Amundi raised its stake in shares of Astera Labs by 77.9% in the first quarter. Amundi now owns 1,880,830 shares of the company’s stock valued at $206,139,000 after acquiring an additional 823,477 shares during the period. Hedge funds and other institutional investors own 60.47% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on ALAB shares. Zacks Research lowered shares of Astera Labs from a “strong-buy” rating to a “hold” rating in a report on Monday, October 5th. Royal Bank Of Canada lifted their price target on shares of Astera Labs from $425.00 to $500.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 5th. Bank of America upped their price target on shares of Astera Labs from $240.00 to $450.00 and gave the company a “neutral” rating in a report on Tuesday, June 23rd. Needham & Company LLC increased their price objective on shares of Astera Labs from $260.00 to $425.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Finally, Stifel Nicolaus increased their price objective on shares of Astera Labs from $260.00 to $460.00 and gave the stock a “buy” rating in a research report on Wednesday, June 24th. Eleven investment analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. According to MarketBeat, Astera Labs has an average rating of “Moderate Buy” and an average price target of $348.33.

Check Out Our Latest Analysis on Astera Labs

Insider Activity

In other news, General Counsel Philip Mazzara sold 6,801 shares of the company’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $340.50, for a total value of $2,315,740.50. Following the transaction, the general counsel directly owned 96,542 shares in the company, valued at approximately $32,872,551. This represents a 6.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Stefan Dyckerhoff sold 8,994 shares of the firm’s stock in a transaction dated Wednesday, October 7th. The stock was sold at an average price of $376.06, for a total transaction of $3,382,283.64. Following the completion of the transaction, the director directly owned 2,648 shares in the company, valued at $995,806.88. This represents a 77.25% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 408,558 shares of company stock valued at $127,306,034. Insiders own 10.40% of the company’s stock.

Astera Labs Stock Up 0.3%

ALAB traded up $0.76 during trading hours on Monday, reaching $286.58. 2,856,952 shares of the company’s stock traded hands, compared to its average volume of 5,151,183. The firm has a 50-day moving average price of $314.86 and a 200 day moving average price of $298.39. The firm has a market capitalization of $49.72 billion, a PE ratio of 141.87 and a beta of 3.68. Astera Labs, Inc. has a 52-week low of $97.89 and a 52-week high of $499.48.

Astera Labs (NASDAQ:ALAB – Get Free Report) last released its earnings results on Tuesday, August 4th. The company reported $0.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.69 by $0.11. Astera Labs had a return on equity of 19.24% and a net margin of 30.74%. The business had revenue of $392.40 million for the quarter, compared to analyst estimates of $360.85 million. During the same quarter last year, the firm posted $0.44 earnings per share. The business’s revenue was up 104.5% compared to the same quarter last year. Astera Labs has set its Q3 2026 guidance at 1.160-1.210 EPS. Equities analysts predict that Astera Labs, Inc. will post 2.70 EPS for the current fiscal year.

About Astera Labs

(Free Report)

Astera Labs, Inc is a semiconductor and connectivity solutions company that develops hardware and software for data centers, cloud computing, and artificial intelligence infrastructure. Its products are designed to help move data between processors, memory, storage, and networking components while addressing bandwidth, latency, and system-management requirements.

The company’s portfolio includes Aries PCI Express and Compute Express Link (CXL) Smart Retimers, Taurus Ethernet Smart Cable Modules, Scorpio Smart Fabric Switches, and Leo CXL Memory Connectivity Controllers.